Internet group Tencent and healthcare system Intermountain Healthcare have exited US-based genomics software developer Tute Genomics in an acquisition by genomic analysis company PierianDx, which paid an undisclosed amount.
Founded in 2012, Tute Genomics has developed a bioinformatics software platform, and its constitutional and exome testing capabilities will be added to PierianDx’s offering post-acquisition.
Ted Briscoe, chief executive of PierianDx, said: “The enhanced platform will provide labs with a single clinical solution to support a comprehensive range of molecular testing for personalised medicine.”
Tencent and Intermountain took part in a $6.7m series A round closed by Tute in June 2015 that included Eurovestech, Peak Ventures, Healthbox and various angel investors.
Tute had raised $8.5m in total, with its other backers including pharmaceutical chemistry provider Wilmington Pharmatech, Salt Lake Life Sciences Angels, Peak Ventures and Park City Angel Network.